{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Transplant+Recipient&page=3",
    "query": {
      "condition": "Lung Transplant Recipient",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 82,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Transplant+Recipient&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Transplant+Recipient&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T13:30:16.005Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06018766",
      "title": "LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bronchiolitis Obliterans Syndrome",
        "Chronic Lung Allograft Dysfunction",
        "Lung Transplantation"
      ],
      "interventions": [
        {
          "name": "LAM-001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Steven Hays, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2023-08-17",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-10-07T13:30:16.005Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06018766"
    },
    {
      "nct_id": "NCT05041140",
      "title": "Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary Impairment",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pulmonary",
        "Pneumonia",
        "Hematopoietic System--Cancer"
      ],
      "interventions": [
        {
          "name": "29-XeMRI imaging",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2024-08-14",
      "completion_date": "2027-07-20",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-10-07T13:30:16.005Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05041140"
    },
    {
      "nct_id": "NCT05041426",
      "title": "Letermovir for CMV Prevention After Lung Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Transplant",
        "CMV"
      ],
      "interventions": [
        {
          "name": "Letermovir",
          "type": "DRUG"
        },
        {
          "name": "Valganciclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fernanda P Silveira, MD, MS",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 15,
      "start_date": "2021-12-06",
      "completion_date": "2025-03-03",
      "has_results": true,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-10-07T13:30:16.005Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05041426"
    },
    {
      "nct_id": "NCT07538336",
      "title": "Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Transplant"
      ],
      "interventions": [
        {
          "name": "Emapalumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2026-11-02",
      "completion_date": "2028-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-10-07T13:30:16.005Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • San Francisco, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07538336"
    },
    {
      "nct_id": "NCT03625687",
      "title": "Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Respiratory Failure",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2019-02-05",
      "completion_date": "2022-04-04",
      "has_results": true,
      "last_update_posted_date": "2023-04-25",
      "last_synced_at": "2026-10-07T13:30:16.005Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03625687"
    },
    {
      "nct_id": "NCT05220397",
      "title": "Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney Transplant Recipient"
      ],
      "interventions": [
        {
          "name": "Janssen Ad26.CoV2.S Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Reduction in Immunosuppression Medication",
          "type": "OTHER"
        },
        {
          "name": "Maintenance in Immunosuppression Medication",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Mark Stegall",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 468,
      "start_date": "2022-04-11",
      "completion_date": "2025-02-28",
      "has_results": true,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-10-07T13:30:16.005Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05220397"
    },
    {
      "nct_id": "NCT07092865",
      "title": "A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "Adjuvanted RSVPreF3 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 168,
      "start_date": "2025-08-06",
      "completion_date": "2027-07-16",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-07T13:30:16.005Z",
      "location_count": 7,
      "location_summary": "Lexington, Kentucky • St Louis, Missouri • Omaha, Nebraska + 3 more",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07092865"
    },
    {
      "nct_id": "NCT06033196",
      "title": "Tocilizumab in Lung Transplantation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Transplant"
      ],
      "interventions": [
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 350,
      "start_date": "2024-02-13",
      "completion_date": "2029-01-08",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-07T13:30:16.005Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06033196"
    },
    {
      "nct_id": "NCT05037851",
      "title": "An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Aspergillosis"
      ],
      "interventions": [
        {
          "name": "Opelconazole",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pulmocide Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2021-11-19",
      "completion_date": "2023-11-13",
      "has_results": true,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-10-07T13:30:16.005Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05037851"
    },
    {
      "nct_id": "NCT01502072",
      "title": "Respiratory Syncytial Virus - RSV Protocol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bone Marrow Transplant Infection",
        "Infection in Marrow Transplant Recipients",
        "Respiratory Syncytial Virus Infections",
        "Respiratory Syncytial Virus Pneumonia",
        "Cancer",
        "Acute Leukemia"
      ],
      "interventions": [
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2011-12-28",
      "completion_date": "2020-02-01",
      "has_results": true,
      "last_update_posted_date": "2021-02-15",
      "last_synced_at": "2026-10-07T13:30:16.005Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01502072"
    }
  ]
}